Compass Therapeutics (CMPX) Total Current Liabilities (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Total Current Liabilities data on file, last reported at $10.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 31.01% year-over-year to $10.3 million; the trailing twelve-month figure through Mar 2026 stood at $10.3 million (down 31.01% YoY), and the FY2025 full-year result was $14.0 million, up 57.4% from the prior year.
• Total Current Liabilities slipped to $10.3 million in Q1 2026, from $14.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $16.2 million in Q4 2022 to a low of $3.9 million in Q1 2024.
• A 5-year average of $10.3 million and a median of $9.7 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slumped 65.21% in 2024 and soared 282.74% in 2025, its largest moves.
• Tracing CMPX's Total Current Liabilities over 5 years: stood at $16.2 million in 2022, then tumbled by 51.75% to $7.8 million in 2023, then grew by 13.75% to $8.9 million in 2024, then surged by 57.4% to $14.0 million in 2025, then slipped by 26.41% to $10.3 million in 2026.
• Business Quant data shows CMPX's Total Current Liabilities at $10.3 million in Q1 2026, $14.0 million in Q4 2025, and $12.4 million in Q3 2025.